

## Putting NICE guidance into practice

# Costing statement:

**Ombitasvir/paritaprevir/ritonavir and dasabuvir (3D) for treating chronic hepatitis C genotype 1**  
**Ombitasvir/paritaprevir/ritonavir (2D) for treating chronic hepatitis C genotype 4 (TA365)**

Published: November 2015

NHS England commissions this technology.

The contract prices used for decision-making in this appraisal are the relevant prices the NHS pays for ombitasvir–paritaprevir–ritonavir and dasabuvir. These prices are based on contract pricing arrangements between the company and the Commercial Medicines Unit.

This statement is supported by a local costing template, but unit costs are not included because these drug regimens have a discount which is commercial in confidence. Once the cost of the drug is obtained, the user needs to input this cost into the light blue blank cells on the unit costs worksheet in the local costing template.

This costing statement accompanies the NICE technology appraisal guidance on [Ombitasvir/paritaprevir/ritonavir and dasabuvir \(3D\) for treating chronic hepatitis C genotype 1](#), [Ombitasvir/paritaprevir/ritonavir \(2D\) for treating chronic hepatitis C genotype 4](#) and should be read in conjunction with it. See [terms and conditions](#) on the NICE website.

© National Institute for Health and Care Excellence, 2015. All rights reserved.

This material may be freely reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the express written permission of NICE.